SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SABS) (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
SIOUX FALLS, S.D., Nov. 03, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SABS) (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing ...
SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results